Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type)

Atherosclerosis. 2012 Jan;220(1):72-7. doi: 10.1016/j.atherosclerosis.2011.10.006. Epub 2011 Oct 12.

Abstract

Objective: The aim of this study was to compare the effects of HDL(Milano) and HDL(wild-type), on regression and stabilization of atherosclerosis.

Methods: Atherosclerotic New Zealand White rabbits received 2 infusions, 4 days apart, of HDL(Milano) (75mg/kg of apoA-I(Milano)), HDL(wild-type) (75mg/kg apoA-I(wild-type)) or placebo. Pre- and post-treatment plaque volume was assessed by MRI. Markers of plaque vulnerability and inflammation were evaluated. Liver and aortic cholesterol content, aortic ABCA-1 and liver SR-BI were quantified. The effect of apoA-I Milano and wild-type proteins on MCP-1 and COX-2 expression by macrophages was evaluated in vitro.

Results: Both forms of HDL induced aortic plaque regression (-4.1% and -2.6% vs. pre-treatment in HDL(Milano) and HDL(wild-type) respectively, p<0.001 and p=0.009). A similar reduction in cholesterol content of aorta and liver was observed with both treatments vs. placebo. The expression of aortic ABCA-1 and hepatic SR-BI was significantly higher in both treated groups vs. placebo. A significantly reduced plaque macrophage density was observed in the HDL(Milano) vs. both HDL(wild-type) and placebo groups. Plaque levels of COX-2, MCP-1, Caspase-3 antigen and MMP-2 activity were significantly reduced in the HDL(Milano) vs. both HDL(wild-type) and placebo groups. In vitro studies showed that apoA-I(Milano) protein significantly reduced expression of COX-2 and MCP-1 in oxLDL loaded macrophages vs. apoA-I(wild-type).

Conclusions: Despite a similar effect on acute plaque regression, the infusion of HDL(Milano) exerts superior anti-inflammatory and plaque stabilizing effects than HDL(wild-type) in the short term.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter 1
  • ATP-Binding Cassette Transporters / metabolism
  • Animals
  • Anti-Inflammatory Agents / administration & dosage*
  • Antioxidants / administration & dosage
  • Aorta, Abdominal / drug effects
  • Aorta, Abdominal / metabolism
  • Aorta, Abdominal / pathology
  • Aortic Diseases / blood
  • Aortic Diseases / drug therapy*
  • Aortic Diseases / pathology
  • Apolipoprotein A-I / administration & dosage*
  • Atherosclerosis / blood
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / pathology
  • CD36 Antigens / metabolism
  • Caspase 3 / metabolism
  • Cell Line
  • Chemokine CCL2 / metabolism
  • Cholesterol / metabolism
  • Cyclooxygenase 2 / metabolism
  • Disease Models, Animal
  • Infusions, Intravenous
  • Lipid Peroxidation / drug effects
  • Lipoproteins, HDL / administration & dosage*
  • Lipoproteins, LDL / metabolism
  • Liver / drug effects
  • Liver / metabolism
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Magnetic Resonance Imaging
  • Matrix Metalloproteinase 2 / metabolism
  • Oxidative Stress / drug effects
  • Phosphatidylcholines / administration & dosage*
  • Rabbits
  • Recombinant Proteins / administration & dosage
  • Time Factors

Substances

  • ATP Binding Cassette Transporter 1
  • ATP-Binding Cassette Transporters
  • Anti-Inflammatory Agents
  • Antioxidants
  • Apolipoprotein A-I
  • CCL2 protein, human
  • CD36 Antigens
  • Chemokine CCL2
  • ETC216
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Phosphatidylcholines
  • Recombinant Proteins
  • apolipoprotein A-I Milano
  • oxidized low density lipoprotein
  • Cholesterol
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Caspase 3
  • Matrix Metalloproteinase 2